Individuals at increased genetic risk for developing type 2 diabetes and metabolic syndrome-a cluster of metabolic and cardiovascular diseases tied to obesity and diabetes-need improved inexpensive and sustainable cardiovascular medicine.
In a review by investigators from The University of Texas Health Science Center at Houston (UTHealth) in the open-access journal PLOS ONE Antibodies associated with subclinical cardiovascular disease and metabolic syndrome in clinical populations: a systematic review and meta-analysis the researchers found a statistically significant positive association between low dose aspirin (LD) coenzyme Q (CQ) beta-blockers (BetaB) and beta-blockers plus metformin (Metformin) and low-dose aspirin (LD).
Developing therapeutic strategies using targeted treatments to moderate the effects of high-dose aspirin and -blockers alone or in combination with Metformin in patients at the genetic risk level needed additional trial and control analyses.
Danielle Baker Ph. D. from Harvard T. H. Chan School of Public Health who led the review and meta-analysis.
The discovery of new mechanisms associated with susceptibility to COVID-19 that require further study is particularly laudatory given the so-called giants surrounding us such as humans bacteria and microbes the authors noted. These particles are about the size of humans and have 2000 times the diameter.
It took about 30 years of strain: sizeable and sustained study and parallel research. The magnitude of effect of meta-analysis is too good to be due to chance. Large-scale trials to test individual treatments and combinations are possible and well-conducted. These trials happen in parallel with the clinical studies and are able to answer important important questions that are by definition open questions.